JP7390370B2 - 妊娠中のｆｇｆｒ３関連骨疾患の処置ためのインフィグラチニブ - Google Patents

妊娠中のｆｇｆｒ３関連骨疾患の処置ためのインフィグラチニブ Download PDF

Info

Publication number
JP7390370B2
JP7390370B2 JP2021516939A JP2021516939A JP7390370B2 JP 7390370 B2 JP7390370 B2 JP 7390370B2 JP 2021516939 A JP2021516939 A JP 2021516939A JP 2021516939 A JP2021516939 A JP 2021516939A JP 7390370 B2 JP7390370 B2 JP 7390370B2
Authority
JP
Japan
Prior art keywords
fgfr3
treatment
achondroplasia
bone disease
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502408A5 (https=
JPWO2020065034A5 (https=
JP2022502408A (ja
Inventor
ルジェ－マル，ロランス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Fondation Imagine
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Fondation Imagine
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Fondation Imagine, Universite Paris Cite filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of JP2022502408A publication Critical patent/JP2022502408A/ja
Publication of JP2022502408A5 publication Critical patent/JP2022502408A5/ja
Publication of JPWO2020065034A5 publication Critical patent/JPWO2020065034A5/ja
Application granted granted Critical
Publication of JP7390370B2 publication Critical patent/JP7390370B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021516939A 2018-09-28 2019-09-27 妊娠中のｆｇｆｒ３関連骨疾患の処置ためのインフィグラチニブ Active JP7390370B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306275.1 2018-09-28
EP18306275 2018-09-28
PCT/EP2019/076241 WO2020065034A1 (en) 2018-09-28 2019-09-27 Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy

Publications (4)

Publication Number Publication Date
JP2022502408A JP2022502408A (ja) 2022-01-11
JP2022502408A5 JP2022502408A5 (https=) 2022-07-07
JPWO2020065034A5 JPWO2020065034A5 (https=) 2022-07-07
JP7390370B2 true JP7390370B2 (ja) 2023-12-01

Family

ID=63798918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516939A Active JP7390370B2 (ja) 2018-09-28 2019-09-27 妊娠中のｆｇｆｒ３関連骨疾患の処置ためのインフィグラチニブ

Country Status (5)

Country Link
US (2) US20220040175A1 (https=)
EP (1) EP3856187B1 (https=)
JP (1) JP7390370B2 (https=)
ES (1) ES3025795T3 (https=)
WO (1) WO2020065034A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250198A1 (en) * 2020-06-11 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of fgfr3-related cognitive deficit
CA3202267A1 (en) * 2020-12-18 2022-06-23 Riccardo Panicucci Methods of treating achondroplasia
EP4452271A1 (en) * 2021-12-20 2024-10-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of a fgfr3 tyrosine kinase inhibitor for the treatment of fgfr-related bone repair and bone formation impairments
JP2026507903A (ja) * 2023-03-06 2026-03-06 キューイーディー セラピューティクス，インコーポレイテッド 骨格形成異常の治療方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150011560A1 (en) 2011-12-12 2015-01-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133328B2 (en) * 2011-12-12 2015-09-15 Sa Des Eaux Minerales D'evian Saeme Plastic compositions and containers made thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150011560A1 (en) 2011-12-12 2015-01-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia，Human Molecular Genetics，2012年，vol.21, no.26，pp.5443-5455，doi:10.1093/hmg/dds390
Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia，J Neurosurg Pediatr，2017年，vol.19，pp.91-95，DOI: 10.3171/2016.7.PEDS16199
Meckel’s and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible，Human Molecular Genetics，2016年，vol.25, no.14，pp.2997-3010，doi: 10.1093/hmg/ddw153
Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates SLC26A2-deficient chondrodysplasias，EBioMedicine，2019年01月23日，vol.40，pp.695-709，https://doi.org/10.1016/j.ebiom.2019.01.010
Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model，The Journal of Clinical Investigation，2016年，vol.126, no.5，pp.1871-1884，doi:10.1172/JCI83926

Also Published As

Publication number Publication date
EP3856187B1 (en) 2025-03-12
WO2020065034A1 (en) 2020-04-02
EP3856187A1 (en) 2021-08-04
ES3025795T3 (en) 2025-06-09
US20240285626A1 (en) 2024-08-29
JP2022502408A (ja) 2022-01-11
US20220040175A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
JP7390370B2 (ja) 妊娠中のｆｇｆｒ３関連骨疾患の処置ためのインフィグラチニブ
JP2020203889A (ja) 抗体製剤
JP2009538274A (ja) Ｃｘｃｌ１３またはｃｘｃｒ５のアンタゴニストの創傷または線維症疾患の治療のための使用
CN101951941A (zh) 抑制瘢痕形成的方法
WO2004056352A1 (en) TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS
US20240358704A1 (en) Combined administration
BR112013014642A2 (pt) produto farmacêutico, kit, uso, produtos, métodos e usos inovadores
JP2006521405A (ja) 発作回復におけるエリトロポイエチンの使用
JP6232630B2 (ja) 骨系統疾患治療薬及びその用途
Matsushita et al. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia
JP2024524277A (ja) Ｇｌｐ－１ｒアゴニストを含む医薬組成物
EP3254698A1 (en) Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
RU2655811C2 (ru) Терапевтическое средство для бокового амиотрофического склероза
WO2025051248A1 (zh) 一种治疗骨关节炎的药物
CN117085133B (zh) Csf1r受体及其抑制剂的用途
EP2162129B1 (en) Use of hdac inhibitors for the treatment of bone destruction
US20210347877A1 (en) Pharmaceutical composition comprising antibody, device comprising same, and use thereof
WO2021219101A1 (zh) 一种含杂环的化合物的应用
CN116887822A (zh) 治疗软骨发育不全的方法
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
JP2007505892A (ja) 向上した成長障害の処置方法
JP2007523827A (ja) 混合性白血病遺伝子の再構成を伴う急性リンパ芽球性白血病の処置方法
US20190247405A1 (en) Treatment of sma
TWI676482B (zh) 盤基蛋白結構域受體１的抑制劑及活化劑及其用途
CN120420414A (zh) 含有人工合成的促皮质素类似物的组合物、其制备方法以及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231120

R150 Certificate of patent or registration of utility model

Ref document number: 7390370

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150